Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06142188
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-21
First Post:
2023-11-15
Brief Title:
Relmacabtagene Autoleucel in Hematologic Malignancies
Sponsor:
Shanghai Ming Ju Biotechnology Co Ltd
Organization:
Shanghai Ming Ju Biotechnology Co Ltd
Study Overview
Official Title:
A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Detailed Description:
The purpose of this study is to observationally evaluate the efficacy and safety data of Relmacabtagene Autoleucel for the treatment of patients with hematologic malignancies for up to 15 years after infusion The treating physician will determine the most appropriate diagnostic and therapeutic regimen for the patient based on clinical practice No therapeutic intervention will be administered to patients in this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None